Amgen, Merck & Co, Pfizer, Intermountain and McKesson were among the investors to jointly acquire a majority of the clinical trials software producer's shares.
A consortium that includes several corporate venturing units have combined to pay $430m for a majority stake in US-headquartered clinical software provider Saama Technologies.
Private equity firm Carlyle led the deal, which also featured pharmaceutical firms Amgen, Merck & Co and Pfizer, health system Intermountain, medical product distributor McKesson, Northpond Ventures and Population Health Partners.
The corporates invested through respective subsidiaries Amgen Ventures, Merck Global Health Innovation Fund, Pfizer Ventures, Intermountain Ventures and McKesson Ventures.
Saama has built a cloud…
